Navigation Links
GenVec Announces Update of Safety and Efficacy Data from Pivotal,Phase II/III PACT Study of TNFerade at ASCO

Ferade(TM), is currently in a pivotal Phase II/III study (PACT) in locally advanced pancreatic cancer; Phase II studies are in progress in rectal cancer and melanoma; and Phase I/II studies are in progress in head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and seasonal and pandemic flu. Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Preliminary clinical trial data cannot be considered predictive of final trial outcome. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Excha
'"/>




Page: 1 2 3 4

Related medicine technology :

1. GenVec Presents Research on New Ad35 Adenovector at ARVO
2. GenVec Announces New Research at AACR on Selectivity and Mechanism of Action of TNF-Based Anti-Cancer Therapy
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
(Date:7/30/2015)... , July 30, 2015 Tianyin Pharmaceutical ... pharmaceutical company that specializes in the patented biopharmaceutical, modernized ... ingredients (API), provided updates regarding the notice it received ... (the "Exchange") indicating that the Company was below certain ... in Sections 134 and 1101 of the NYSE MKT ...
(Date:7/30/2015)... PARSIPPANY, N.J. , July 30, 2015  Growth ... Rx-to-OTC switches as they bring former prescription users to ... environment, Kline forecasts robust Rx-to-OTC switch activity ... OTC categories emerging along with many new brands entering ... switches occur over the next five years (even those ...
(Date:7/30/2015)... 30, 2015  Medimetriks Pharmaceuticals, Inc. announced today ... III clinical study for Ozenoxacin, a novel bactericidal ... the exclusive U.S. rights to Ozenoxacin 1% cream.  ... 44 centers with an emphasis on U.S. patients, ... months and older with a clinical diagnosis of ...
Breaking Medicine Technology:TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 2Medimetriks Pharmaceuticals, Inc. Announces Completion of the Second Successful Pivotal Phase III Study for Ozenoxacin 3
... ARAY ), a global leader in the field ... present at the 10th Annual Needham Healthcare Conference in New ... ET/7:00 a.m. PT. A live webcast of the ... of the Company,s Web site at http://www.accuray.com . The ...
... March 28, 2011 JHP Pharmaceuticals, a leading ... products, has entered into a multi-year contract-manufacturing agreement ... responsible for manufacturing and supply of a sterile ... Stuart Hinchen, president and co-founder of JHP noted, ...
Cached Medicine Technology:Accuray Incorporated to Speak at 10th Annual Needham Healthcare Conference 2JHP Pharmaceuticals Announces Multi-Year Contract Manufacturing Agreement 2
(Date:8/1/2015)... ... August 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe Organic ... very first small business donation to kick off the campaign for healing and Well-Being. ... legacy includes a complete line of raw, organic hair care products, as well as ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a reputable source of authentic tickets for ... Arena. Fans of every genre of music will have an act they are excited ... of the festival, the following artists will perform: Sam Smith, Coldplay, Kenny Chesney, The ...
(Date:7/31/2015)... ... ... Ticket Down is a reliable source for authentic tickets for the 2015 ... The festival will end on Sunday, August 2nd. , Music fans have ... This unique and unbelievably popular festival attracts the best in entertainment from around the ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight ... Memphis on October 3, 2015. The Ride to Fight On is a cycling fundraiser ... Methodist Healthcare, The West Clinic and The University of Tennessee Health Science Center. A ...
(Date:7/31/2015)... Rolling Meadows, IL (PRWEB) , ... July 31, ... ... great ways to communicate. Rally Insurance Group, Inc. has re-branded their social media ... provides a personal way for consumers to communicate, find information, share insights ...
Breaking Medicine News(10 mins):Health News:March4thforWellBeing Foundation Kickoff 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 2Health News:Cheap 2015 iHeartRadio Music Festival Tickets in Las Vegas at MGM Grand Garden Arena: Ticket Down Slashes Ticket Prices on the iHeart Radio Music Festival in Vegas 3Health News:Cheap 2015 Lollapalooza Tickets: Ticket Down Slashes Ticket Prices on Lollapalooza Tickets at Grant Park in Chicago for Saturday, August 1st and Sunday, August 2nd 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2
... Time for Spring Break and Summer MonthsCOLD SPRING HARBOR, N.Y., ... ear health and creator of EarPlanes(R) and ... ClearEars are revolutionary earplugs containing an FDA approved ... the ears after swimming, or even bathing, can lead to ...
... to Launch Heritage Tributes Line of Caskets in ... Heritage Casket Company, an Irish-owned memorial products company, ... memorialization and death care industries, today announced a ... for the marketing and distribution of a new ...
... dangers from inhalants at lowest point since 1991 , , ... percent of American adolescents who use drugs started by ... and air fresheners to get high, according to a ... by youths 12 to 17 years old include refrigerant ...
... Provider Teams Up with Specialty Print Packaging Materials Company to ... ... Southborough, MA (PRWEB) March 16, 2009 ... trace technology and services provider, recently entered into a collaboration ...
... LAUDERDALE, Fla. and HONG KONG, March 16 OrbusNeich ... manufacturer and marketer of innovative medical devices for the ... filed a lawsuit against Boston Scientific Corporation ("BSC"). ... for the Eastern District of Virginia, asserts claims against ...
... Saving Tips to Prevent Accidental PoisoningSAN FRANCISCO, March ... reported each year to poison control centers across ... Control System (CPCS) is dedicated to providing residents ... relating to poisoning. National Poison Prevention Week, ...
Cached Medicine News:Health News:Leader in Ear Care Health Category Expands Product Line 2Health News:Irish-Owned Heritage Casket Company Strikes Multi-Million-Dollar Partnership Deal With Pennsylvania's Matthews International 2Health News:Fewer Teens Sniffing Glue, Household Products 2Health News:Fewer Teens Sniffing Glue, Household Products 3Health News:PHARMORX Security And MSO Announce Joint Venture 2Health News:PHARMORX Security And MSO Announce Joint Venture 3Health News:OrbusNeich Files Patent Infringement Lawsuit Against Boston Scientific 2Health News:OrbusNeich Files Patent Infringement Lawsuit Against Boston Scientific 3Health News:Poison Prevention Week March 15 - 22 2Health News:Poison Prevention Week March 15 - 22 3
Joseph skin hook is a single end-sharp with 2 prong....
Experience great vision, comfort and durability in a quarterly-replacement lens....
A unique lens system featuring Balanced Progressive Technology for optimum vision quality at every distance....
The proven daily wear spherical soft contact lens....
Medicine Products: